Hipolin Limited Reports Significant Net Loss for FY 2025
Hipolin Limited (BSE: 530853) reported financial results for FY 2025. Consolidated net loss increased by 270% to ₹327.75 crore, while total income grew by 8.5% to ₹2,193.37 lakh. Total expenditure rose by 19.5% to ₹2,521.07 crore. Earnings per share declined from -₹2.83 to -₹10.47. The company's Board of Directors approved the audited financial statements in a meeting on May 29, 2025.
*this image is generated using AI for illustrative purposes only.
Hipolin Limited , a company listed on the Bombay Stock Exchange (BSE: 530853), has reported its financial results for the fiscal year ended March 31, 2025. The company's Board of Directors approved both standalone and consolidated audited financial statements in a meeting held on May 29, 2025.
Financial Performance
The company's financial performance for FY 2025 shows a substantial increase in net loss and a slight improvement in total income. Here's a breakdown of the key financial metrics:
| Metric | FY 2025 | FY 2024 | Change |
|---|---|---|---|
| Consolidated Net Loss | ₹327.75 crore | ₹88.61 crore | 270.00% |
| Total Income | ₹2,193.37 lakh | ₹2,021.46 lakh | 8.50% |
| Total Expenditure | ₹2,521.07 crore | ₹2,110.02 crore | 19.50% |
| Earnings Per Share (EPS) | -₹10.47 | -₹2.83 | -270.00% |
Key Highlights
Deepening Losses: Hipolin Limited's consolidated net loss widened significantly, increasing by 270% year-over-year.
Revenue Growth: Despite the increased loss, the company managed to grow its total income by 8.5% compared to the previous year.
Rising Expenses: Total expenditure saw a notable increase of 19.5%, outpacing the growth in income.
Negative EPS: The company's earnings per share deteriorated from -₹2.83 to -₹10.47, reflecting the impact of the increased net loss.
Subsidiary Inclusion: The consolidated financial statements include the results of Jayantilal Bhogilal Chemicals Private Limited, a wholly-owned subsidiary of Hipolin Limited.
Share Capital: The paid-up equity share capital remained at ₹313.13 crore, with shares having a face value of ₹10 each.
Board Meeting Details
As per the company's filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors convened on May 29, 2025, to approve these financial results. The meeting, which started at 7:00 PM and concluded at 10:00 PM, also included discussions on other business transactions.
The financial results were accompanied by a Limited Review Report from the company's Statutory Auditor, adding credibility to the reported figures.
While Hipolin Limited has shown some improvement in its top-line performance, the significant increase in net loss and expenditure raises concerns about the company's financial health and operational efficiency.
Historical Stock Returns for Hipolin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.36% | -8.52% | -6.51% | -30.75% | -42.80% | +132.55% |
17
